atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
Posted:
atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced a strategic investment in Beckley Psytech Limited (“Beckley Psytech”), a private clinical-stage biotechnology company dedicated to transforming short-duration psychedelics into effective and rapid-acting medicines for neuropsychiatric conditions.
Medway NHS Foundation Trust, one of the largest and most innovative NHS trusts in the South-East of England, has taken a bold step forward in its virtual care journey by transitioning to a new digital platform – part of its…
Chancellor Rachel Reeves announced that the government is investing up to £10bn to bring the NHS “into the digital age” as part of the latest spending review.
Read more here.
Attendees
Sponsors and Exhibitors
Contact us